PHIO

Phio Pharmaceuticals Corp. PHIO

NasdaqSmall CapHealthcare

13F Pro Quality Score

Not in ranked universe

Below size threshold

Below the main board's size threshold of $25M annual revenue or $100M total assets. This company reported $0.4M in revenue and is scored on the micro-cap board instead.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

Net income

$-4.14M

Quarter to Jun 30

Free cash flow

$-4.04M

Quarter to Jun 30

Top Institutional Holders

as of Q2 2026
$662.6K total
JANE STREET GROUP, LLC
$120.7K-1.2%
GEODE CAPITAL MANAGEMENT, LLC
$117.4K-22.2%
VANGUARD CAPITAL MANAGEMENT LLC
$96.6K+18.0%
NOMURA ASSET MANAGEMENT INTERNATIONAL INC.
$51.0KNew
Cetera Investment Advisers
$48.7K+5.6%
CITADEL ADVISORS LLC
$48.3KNew
VANGUARD FIDUCIARY TRUST CO
$39.1K0.0%
NORTHERN TRUST CORP
$28.5K+16.9%
TWO SIGMA INVESTMENTS, LP
$22.0K-33.8%
XTX Topco Ltd
$18.9K-25.7%
HRT FINANCIAL LP
$13.0K-62.0%
BRIDGEWAY CAPITAL MANAGEMENT, LLC
$12.3KNew
CITIGROUP INC
$11.9K+1032.2%
CAPTRUST FINANCIAL ADVISORS
$10.3K0.0%
Tower Research Capital LLC (TRC)
$6.4K-18.6%
MORGAN STANLEY
$6.2K0.0%
UBS Group AG
$5.5K-80.0%
OSAIC HOLDINGS, INC.
$2.1K0.0%
Spire Wealth Management
$2.0K-0.5%
SBI Securities Co., Ltd.
$1.3K+1.9%
BARCLAYS PLC
$237New
ASSETMARK, INC
$1130.0%
Activest Wealth Management
$90.0%
Caitong International Asset Management Co., Ltd
$6+100.0%
See all 24 institutional holders →
Reading the latest SEC filing…

Key Metrics

Net Income

Q2 2026
EDGAR

Free Cash Flow

Q2 2026
EDGAR

Financial Trends

Revenue & Net Income

13fpro.ai/company/PHIO

Earnings Per Share

13fpro.ai/company/PHIO

Loading ratio trend…

PHIO key financials by period

Reported revenue, net income and operating margin by fiscal year, from Phio Pharmaceuticals Corp.'s annual filings on SEC EDGAR.

Phio Pharmaceuticals Corp. reported revenue, net income and margins by fiscal period, from SEC filings.
PeriodRevenueNet incomeOp. margin
FY 2019$21.0K$-8.9M—
FY 2018$138.0K$-7.4M—
FY 2017$15.0K$-12.5M—
FY 2016$19.0K$-9.0M—
FY 2015$34.0K$-10.2M—
FY 2013$399.0K$-20.9M—
Source: PHIO filings on SEC EDGAR →

PHIO insiders

Officers, directors and 10% owners with a Form 4 filed in the last 24 months, most recent first. From SEC EDGAR.

About Phio Pharmaceuticals Corp. (PHIO): stock profile, AI score and financials

Phio Pharmaceuticals Corp. (PHIO) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. PHIO is not currently included in 13F Pro's AI-ranked quality universe — below the main board's size threshold of $25m annual revenue or $100m total assets. this company reported $0.4m in revenue and is scored on the micro-cap board instead. Based on the latest XBRL financial filings (Q2 2026), Phio Pharmaceuticals Corp. reports net income of $-4.1M, free cash flow of $-4.0M. Top institutional holders of PHIO by reported 13-F value include JANE STREET GROUP, GEODE CAPITAL MANAGEMENT, VANGUARD CAPITAL MANAGEMENT, based on the most recent SEC filings. PHIO trades on the Nasdaq exchange and files with the SEC under CIK 1533040. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate PHIO daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Phio Pharmaceuticals Corp. directly from SEC EDGAR.

Financials through the period ended SEC EDGAR: CIK 1533040 →